Related content

Phase II study of sunitinib malate in patients with recurrent high-grade glioma

By Neyns B.   Sadones J.   Chaskis C.   Dujardin M.   Everaert H.   Lv S.   Duerinck J.   Tynninen O.   Nupponen N.   Michotte A.   Greve J.  

Journal of Neuro-Oncology, Vol. 103, Iss. 3, 2011-07 ,pp. : 491-501

Springer Publishing Company

Access to resources Recommend Favorite

Sunitinib malate as first-line treatment for an advanced, poorly differentiated pancreatic neuroendocrine tumor

By Lin Li-Zhu   Li Peng   Chen Han-Rui   Pang Ling-Juan  

Future Oncology, Vol. 9, Iss. 6, 2013-06 ,pp. : 909-913

Future Medicine

Access to resources Recommend Favorite

Therapeutic effect of sunitinib malate and its influence on blood glucose concentrations in a patient with metastatic insulinoma

By Chen Jianpeng   Wang Caixia   Han Junqing   Luan Yi   Cui Yangang   Shen Rong   Sha Dan   Cong Lei   Zhang Zheng   Wang Weibo  

Expert Review of Anticancer Therapy, Vol. 13, Iss. 6, 2013-06 ,pp. : 737-743

Informa Healthcare

Access to resources Recommend Favorite

Long-Term Response and Postsurgical Complete Remissions After Treatment With Sunitinib Malate, an Oral Multitargeted Receptor Tyrosine Kinase Inhibitor, in Patients With Metastatic Renal Cell Carcinoma

By Ayllon Jorge   Beuselinck Benoit   Morel Alexandre   Barrascout Eduardo   Medioni Jacques   Scotte Florian   Oudard Stééphane  

Cancer Investigation, Vol. 29, Iss. 4, 2011-04 ,pp. : 282-285

Informa Healthcare

Access to resources Recommend Favorite

Sunitinib for metastatic renal cell carcinoma

By Mukherji Deborah   Larkin James   Pickering Lisa  

Future Oncology, Vol. 6, Iss. 9, 2010-09 ,pp. : 1377-1385

Future Medicine

Access to resources Recommend Favorite